Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

Santhera Updates Development Strategy

Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, announces today a revised clinical and regulatory strategy aimed at accelerating the development timelines for its lead compound SNT-MC17/idebenone in Friedreich’s Ataxia (FRDA) in the US. These changes are the result of discussions with the FDA (US Food and Drug Administration) following the positive results of the Company’s collaborative clinical trial with the US National Institutes of Health (NIH). It is anticipated that both the number of patients needed for the Phase III clinical study and the trial’s duration could be significantly reduced, thereby shortening the development timelines approximately by half a year as compared to the Company’s previous plans.

Read More: Santhera Updates Development Strategy for SNT-MC17


Event E.jpg


Archived in
  Scientific News



Tagged in
FARA Scientific News

Site Map     Privacy Policy     Service Terms     Log-in     Contact     Charity Navigator